Arrowhead Research | ARWR - 资产



金融业
股票价格
USD
资产
USD 2.11B
现金及等价物
USD 19.69M
流动资产
USD 1.67B
流动负债
USD 283.35M
债务
USD 983.69M
EBIT
USD -154.34M
EBITDA
USD -147.68M
员工
711
EPS每股收益
USD -1.36
股本和储备
USD 465.53M
销售毛利
USD 75.25M
债务利息支出
USD 24.56M
利息收入
USD 16.94M
贷款资金
USD 824.07M
市值
USD 10.5B
净收入
USD -194.28M
营业费用
USD 245.35M
营业利润
USD -170.09M
普通股股本
USD 141.14M
PE价格收益
39.19
税前利润
USD -178.91M
销售收入
USD 75.23M
销售和管理费用
USD 46.63M
股票
USD -173.09M
贸易债权人
USD 27.78M
应收帐款人
USD 8.56M


资产 更改 日
Agios Pharmaceuticals USD 1.11B 76.57M 2026-06
Alnylam Pharmaceuticals USD 5.56B 429.22M 2026-06
Anika Therapeutics USD 183.47M 4.09M 2026-06
Arrowhead Research USD 2.11B 156.25M 2026-06
Heron Therapeutics USD 252.26M 6.05M 2026-06
Incyte USD 7.87B 533.53M 2026-06
Ionis Pharmaceuticals USD 2.99B 455.5M 2026-06
Ligand Pharmaceuticals USD 2.19B 653.77M 2026-06
Merck USD 129.8B 1.12B 2026-06
Moderna USD 10.96B 527M 2026-06
Nektar Therapeutics USD 763.27M 482.86M 2026-03
Novartis USD 122.03B 3.5B 2026-06
Sarepta Therapeutics USD 3.19B 9.58M 2026-06
TG Therapeutics USD 1.64B 110.79M 2026-06
Ultragenyx Pharmaceutical USD 1.26B 32M 2026-06
Vertex Pharmaceuticals USD 27.42B 938.9M 2026-06
Xencor USD 724.96M 11.89M 2026-06